Phase 1 Trial of LMP744 in Recurrent Glioblastoma Shows Potential for New Treatment
A clinical trial is underway to evaluate the safety and efficacy of LMP744, a novel indenoisoquinolone inhibitor, in patients with recurrent glioblastoma.
Asset / Drug
Drug and asset intelligence for LMP744 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.